To address elevated mortality rates and historically entrenched racial inequities in mortality rates, the United States needs targeted efforts at all levels of government. However, few or no all-cause mortality data are available at the local level to motivate and guide city-level actions for health equity within the country's biggest cities.
To provide city-level data on all-cause mortality rates and racial inequities within cities and to determine whether these measures changed during the past decade.
This cross-sectional study used mortality data from the National Vital Statistics System and American Community Survey population estimates to calculate city-level mortality rates for the non-Hispanic Black (Black) population, non-Hispanic White (White) population, and total population from January 2016 to December 2018. Changes from January 2009 to December 2018 were examined with joinpoint regression. Data were analyzed for the United States and the 30 most populous US cities. Data analysis was conduct and health inequities in their jurisdictions to increase awareness and advocacy related to racial health inequities, to guide the allocation of local resources, to monitor trends over time, and to highlight effective population health strategies.A chronic shortage of donor kidneys is compounded by a high discard rate, and this rate is directly associated with biopsy specimen evaluation, which shows poor reproducibility among pathologists. A deep learning algorithm for measuring percent global glomerulosclerosis (an important predictor of outcome) on images of kidney biopsy specimens could enable pathologists to more reproducibly and accurately quantify percent global glomerulosclerosis, potentially saving organs that would have been discarded.
To compare the performances of pathologists with a deep learning model on quantification of percent global glomerulosclerosis in whole-slide images of donor kidney biopsy specimens, and to determine the potential benefit of a deep learning model on organ discard rates.
This prognostic study used whole-slide images acquired from 98 hematoxylin-eosin-stained frozen and 51 permanent donor biopsy specimen sections retrieved from 83 kidneys. Serial annotation by 3 board-certified pathologists served as ground nor kidneys. The model performance improved by analyzing multiple levels of a section, surpassing the capacity of pathologists in the time-sensitive setting of examining donor biopsy specimens. The results indicate the potential of a deep learning model to prevent erroneous donor organ discard.Treatment with golimumab monotherapy in early peripheral Spondyloarthritis (pSpA) results in higher rates of clinical remission compared to treatment in more longstanding disease. When reaching remission, treat-to-target recommendations suggest tapering of treatment. We therefore explored whether addition of methotrexate would permit discontinuation of golimumab in patients with pSpA in sustained clinical remission.
After a 2-year extension phase with golimumab treatment, patients with pSpA reaching clinical remission in the CRESPA-trial were offered a tapering strategy leading to discontinuation of golimumab and replacement by methotrexate monotherapy. Patients were prospectively followed to assess the rate of sustained biological-free clinical remission. In case of relapse of arthritis, enthesitis or dactylitis under methotrexate monotherapy, golimumab was restarted.
Twenty-five of the original 60 pSpA patients, entered the step-down strategy. Currently, only 4 patients (16%) are still in sustained remission under methotrexate monotherapy. In 21 patients (84%), golimumab was re-installed because of relapse of disease activity (n?=?19) or development of adverse events related to methotrexate (n?=?2). Restarting golimumab treatment promptly restored clinical remission in all patients within 12 weeks.
In patients with early pSpA achieving clinical remission after 2 years of golimumab treatment, stepdown therapy to monotherapy with MTX led to high rates of clinical relapse. This underscores the overall weak efficacy of methotrexate in maintaining clinical remission in pSpA.
ClinicalTrials.gov, https//clinicaltrials.gov, NCT01426815.
ClinicalTrials.gov, https//clinicaltrials.gov, NCT01426815.Personalized treatment choices would increase the effectiveness of internet-based cognitive behavioral therapy (iCBT) for depression to the extent that patients differ in interventions that better suit them.
To provide personalized estimates of short-term and long-term relative efficacy of guided and unguided iCBT for depression using patient-level information.
We searched PubMed, Embase, PsycInfo, and Cochrane Library to identify randomized clinical trials (RCTs) published up to January 1, 2019.
Eligible RCTs were those comparing guided or unguided iCBT against each other or against any control intervention in individuals with depression. Available individual patient data (IPD) was collected from all eligible studies. Depression symptom severity was assessed after treatment, 6 months, and 12 months after randomization.
We conducted a systematic review and IPD network meta-analysis and estimated relative treatment effect sizes across different patient characteristics through IPD network meta-regressta-analysis with IPD, guided iCBT was associated with more effectiveness than unguided iCBT for individuals with depression, benefits were more substantial in individuals with moderate to severe depression. Unguided iCBT was associated with similar effectiveness among individuals with symptoms of mild/subthreshold depression. Personalized treatment selection is entirely possible and necessary to ensure the best allocation of treatment resources for depression.
In this network meta-analysis with IPD, guided iCBT was associated with more effectiveness than unguided iCBT for individuals with depression, benefits were more substantial in individuals with moderate to severe depression. https://www.selleckchem.com/products/mito-tempo.html Unguided iCBT was associated with similar effectiveness among individuals with symptoms of mild/subthreshold depression. Personalized treatment selection is entirely possible and necessary to ensure the best allocation of treatment resources for depression.